As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...
Here are two options investors should consider: Johnson & Johnson ( JNJ 0.09%) and Merck ( MRK 1.54%). These two healthcare ...
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens ...
Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...
MedPage Today on MSN
Preservatives and Cancer; Pre-Op Therapy Gains Momentum; Speedier Myeloma Approvals
News, features, and commentary about cancer-related issues ...
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 ...
Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...
Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial da ...
Investor's Business Daily on MSN
Stock market falls, recovers on Trump's Greenland shifts; Intel, Netflix, Tesla key movers: Weekly review
The stock market plunged initially on President Trump's Greenland tariffs, but recovered as he backed off. Intel, Netflix, ...
The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...
Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential ...
Learn how scientists aim to harness the immune system's ability to fight cancer in developing groundbreaking new treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results